ACR exact-submission catalog context
ACR AI Central provides an exact-submission model card for Koios DS for Breast; FDA labeling remains controlling for clinical use, limitations, and performance.
exact submission · checked 2026-09-09FDA-cleared profile
Koios Medical, Inc. · Mammography/DBT · FDA-cleared (510(k))
Authorized purpose: Adjunctive breast-cancer decision support during diagnostic ultrasound for patients referred for further diagnostic ultrasound; classifies a user-selected lesion ROI into four BI-RADS-aligned categories and assesses shape and orientation.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: Adjunctive breast-cancer decision support during diagnostic ultrasound for patients referred for further diagnostic ultrasound; classifies a user-selected lesion ROI into four BI-RADS-aligned categories and assesses shape and orientation.
Evidence takeaway. Evidence from the reviewed source record: FDA clinical reader study: 15 readers evaluated 900 randomized cases in aided and unaided reading periods. The primary endpoint was AUC shift for ultrasound examination plus DS versus ultrasound alone: 0.0370 (95% CI 0.030-0.044). A separate 900-lesion system test reported AUC 88.2%; shape/orientation comparisons are agreement/equivalence endpoints, not sensitivity or specificity.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
This field has not been curated yet.
This field has not been curated yet.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Price not public here; enter your quote
Not verified: Pricing information is recorded but not verified against a resolving source.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: DICOM breast-ultrasound images, typically from small-parts linear-array or dedicated breast ultrasound transducers, with up to two user-selected ROIs representing one lesion.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-09 · FDA K190442: Koios DS for Breast
Source context, not route validation: Web application with ROI processing on an IIS Windows server; accepts DICOM-compliant files, returns results to the compatible client, can save a report as a PACS addendum, and can export to third-party reporting software.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-09 · FDA K190442: Koios DS for Breast
Source context, not route validation: The exact FDA package describes Koios DS for Breast as an ASP.NET web application deployed to an IIS web server in a Windows environment and accessed through a compatible client; user-selected ROIs are sent to the Koios DS for Breast server for processing. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "The software device is a web application that is deployed to a Microsoft IIS web server and accessed by a user through a compatible client." … "The Koios DS for Breast software is an ASP.NET web application that is deployed to an IIS Web Server inside a Windows operating system environment.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-14 · FDA K190442: Koios DS for Breast
Source context, not route validation: Four BI-RADS-aligned categories (Benign, Probably Benign, Suspicious, Probably Malignant), a continuous graphical confidence indicator, lesion shape and orientation classifications, image adjustment/measurement/documentation tools, and structured-report output.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-09 · FDA K190442: Koios DS for Breast
Unresolved route: Four BI-RADS-aligned categories (Benign, Probably Benign, Suspicious, Probably Malignant), a continuous graphical confidence indicator, lesion shape and orientation classifications, image adjustment/measurement/documentation tools, and structured-report output.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-09 · FDA K190442: Koios DS for Breast
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Packet wording: "The software device is a web application that is deployed to a Microsoft IIS web server and accessed by a user through a compatible client." … "The Koios DS for Breast software is an ASP.NET web application that is deployed to an IIS Web Server inside a Windows operating system environment.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The summary states a training requirement for users but does not describe the training program, its content, or its provider.
ACR AI Central provides an exact-submission model card for Koios DS for Breast; FDA labeling remains controlling for clinical use, limitations, and performance.
exact submission · checked 2026-09-09Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public price or quote for the exact K190442 configuration was established in this review.
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
7 sources - 3 history items
Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment
Scope: regulatoryIdentity, modalityContext
Scope: anatomy
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: recallDiscovery, nativeSubmissionMatching
Scope: postmarketSafety
Regulatory record
510(k)
Research record
fda record reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Therapixel
Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.
DeepHealth, Inc.
Authorized purpose: Concurrent detection and characterization support for screening DBT mammography
DeepHealth, Inc.
Authorized purpose: BAC processes screening FFDM and DBT mammograms to detect the presence or absence of breast arterial calcifications at study and breast level and localize detected calcifications for qualified interpreting-physician review.
Neurocareai, Inc. (Dba Savelife.Ai)
Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history